.png)
.png)
SPARTA Biodiscovery raises £3.5 million to accelerate commercial roll-out
A multi-million-pound investment from industry partner Sartorius will support deployment of SPARTA Biodiscovery’s nanoparticle analysers.
Coulter Partners and Institute of Neurodiversity partner to empower innovation
Coulter Partners and the Institute of Neurodiversity partner to empower innovation and promote diversity of thought.
UK set to lead global delivery of next-generation mRNA medicines
BIA's new explainer shows how the UK is leading the way in mRNA, a strategic technology of the future.
UK Regulatory Science community meets to discuss the future of UK Medicine Regulation
Leaders in medicines regulatory science are meeting to chart the course for the future of UK medicine regulation on 5 October at 11 Cavendish Square, London.
CEO Update - 2 October 2023
ICBA Geneva delegation special, party conferences in full swing, BIA fringe event at the Conservative conference, Evotec opening, and Regulatory conference all set for Thursday.
World Heart Day: A reflection on the killer disease
Every year, World Heart Day presents an opportune moment to reflect on the leading cause of death in our global community – cardiovascular disease (CVD).
Mogrify extends Series A financing to $46 million USD
Funding will support advancement of Mogrify’s dedicated pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.
Macomics expands in Edinburgh, appoints Professor Paul Crocker to SAB
Macomics Ltd, a leader in macrophage drug discovery, continues its growth trajectory with expansion in Edinburgh into dedicated facilities within the Roslin Innovation Centre.
Evotec opens new state-of-the-art biology facility on Dorothy Crowfoot Hodgkin Campus
Evotec SE today celebrated the Grand Opening of a new facility, Building 95 (“B95”), on the Company’s Dorothy Crowfoot Hodgkin Campus at Milton Park.
MicrofluidX welcomes new board members and scientific advisor
MicrofluidX, a UK-based developer of technologies that streamline the development and deployment of cell and gene therapies, today announces the appointment of two new board members and an additional scientific advisor to support the company.